Skip to main navigation Skip to search Skip to main content

A clue to the therapy of neurofibromatosis type 2: NF2/Merlin is a PAK1 inhibitor

  • Yumiko Hirokawa
  • , Anjali Tikoo
  • , John Huynh
  • , Tamara Utermark
  • , C. Oliver Hanemann
  • , Marco Giovannini
  • , Guang Hui Xiao
  • , Joseph R. Testa
  • , John Wood
  • , Hiroshi Maruta*
  • *Corresponding author for this work
  • Ludwig Institute for Cancer Research
  • Ulm University
  • Fondation Jean Dausset-Centre d'Etude du Polymorphisme Humain
  • Fox Chase Cancer Center
  • Yale University

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)20-26
Number of pages6
JournalCancer Journal (United States)
Volume10
Issue number1
DOIs
Publication statusPublished - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this